Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Oral Pan-RAF Inhibitor QLH11906 in Subjects With Advanced Solid Tumors Harboring MAPK Pathway Alterations.

Sponsors

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Source Qilu Pharmaceutical Co., Ltd.
Brief Summary

This is an open label, phase 1 clinical study to evaluate the safety and tolerability of different doses of QLH11906 monotherapy in patients with relapsed/refractory, unresectable locally advanced or metastatic advanced solid tumors with abnormal MAPK pathway, and determine the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD, if MTD cannot be determined) and Recommended Dose in Phase II Clinical Studies (Recommended Phase II Dose, RP2D).

Overall Status Recruiting
Start Date 2022-06-14
Completion Date 2025-07-01
Primary Completion Date 2024-07-01
Phase Phase 1
Study Type Interventional
Primary Outcome
Measure Time Frame
MTD/MAD Up to 24 approximately months
RP2D Up to 24 approximately months
Secondary Outcome
Measure Time Frame
Adverse Events (AEs) /Serious Adverse Events (SAEs) Up to 24 approximately months
Area under the concentration-time curve(AUC) Up to 24 approximately months
Overall response rate (ORR) Up to 24 approximately months
Duration of response (DoR) Up to 24 approximately months
Disease control rate (DCR) Up to 24 approximately months
Maximum concentration (Cmax) Up to 24 approximately months
Enrollment 40
Condition
Intervention

Intervention Type: Drug

Intervention Name: QLH11906

Description: QLH11906 only

Arm Group Label: QLH11906

Eligibility

Criteria:

Inclusion Criteria: 1. The subjects participated voluntarily, signed the informed consent, and were able to abide by the research procedures. 2. Subjects with advanced (metastatic or unresectable) solid tumors with histologically confirmed MAPK signaling pathway alteration. 3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. 4. Subjects are able to swallow and retain oral medication without any clinically significant gastrointestinal abnormalities that alter absorption. 5. Subjects (including women and men) agree to use effective contraception for contraception from the time of signing the informed consent form to 180 days after the last use of the study drug. Female subjects of childbearing age cannot be pregnant or breastfeeding. Exclusion Criteria: 1. Subjects received systemic anticancer therapy within 2 weeks prior to the first dose. 2. Subjects received radical radiotherapy within 4 weeks before the first administration, or received local palliative radiotherapy for bone metastases within 1 week. 3. Subjects who have received inhibitors or inducers of CYP3A4 within 1 week before the first dose; or within 5 half-lives of the drug; or subjects who need to continue to receive these drugs during the study period. 4. Active bacterial, fungal, or viral infection requiring systemic therapy within 1 week prior to the first dose. 5. Subjects with symptomatic central nervous system (CNS) metastases and/or cancerous meningitis. 6. Cardiovascular and cerebrovascular diseases with clinical significance. 7. Clinically uncontrollable serous effusion (eg, pleural effusion that cannot be controlled by drainage or other methods). 8. Active gastrointestinal disease or other conditions that significantly interfere with drug absorption. 9. Known immediate or delayed hypersensitivity reactions or idiosyncratic reactions to the investigational treatment-related chemotherapeutic drugs and their excipients. 10. Human immunodeficiency virus (HIV) positive test result and Treponema pallidum antibody positive. 11. Hepatitis B virus surface antigen (HBsAg) positive and viral deoxyribonucleic acid (HBV DNA) > 2000 IU/ml or 104 copies/ml (only the centers that can perform qualitative examination, the HBV DNA test result is positive or high detection limit); hepatitis C virus antibody positive and viral ribonucleic acid (HCV RNA) positive. 12. Other malignant tumors occurred within 2 years before study enrollment. (Except: Bowen's disease; cured basal cell or squamous cell skin cancer; prostate cancer with a Gleason score of 6; treated cervical carcinoma in situ.) 13. Pregnant or lactating women. 14. Any pre-existing serious or unstable disease (except for the above-mentioned malignant tumors), mental disease or any disease or medical condition that the investigator considers may interfere with the subject's safety, obtaining informed consent, or complying with research procedures. 15. Concurrent participation in other clinical trials using experimental therapies.

Gender:

All

Minimum Age:

18 Years

Maximum Age:

N/A

Healthy Volunteers:

No

Overall Contact

Last Name: Lianghua Fang

Phone: 86-13645192882

Email: [email protected]

Location
Facility: Status: Contact: Shandong Cancer Hospital Jinming Yu, MD,PhD 0531-67626971 [email protected]
Location Countries

China

Verification Date

2022-08-01

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: QLH11906

Type: Experimental

Description: QLH11906 Tablets

Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Advanced Solid Tumors Harboring MAPK Pathway Alterations

Clinical Trials on QLH11906